study of palbociclib after cdk & endocrine therapy in er /her2- metastatic breast cancer
Published 5 years ago • 2.5K plays • Length 6:29Download video MP4
Download video MP3
Similar videos
-
2:21
palbociclib with adjuvant endocrine therapy in early breast cancer - pallas study
-
33:41
clinical trials for metastatic breast cancer: what you should know | dana-farber cancer institute
-
29:09
interactive case: choosing and using cdk4/6 inhibitors in breast cancer - first-line therapy
-
5:43
cdk 4/6 inhibitor, palbociclib, for the treatment of metastatic breast cancer
-
7:23
study of ribociclib and pdr001 in hr metastatic breast cancer
-
13:22
palbociclib and breast cancer
-
4:59
study of saci-io for hormone receptor positive metastatic breast cancer
-
39:15
metastatic breast cancer forum 2018: clinical trials 101 | dana-farber cancer institute
-
5:21
study of neratinib for patients with her2-positive breast cancer with brain metastases
-
1:52
breast cancer research at esmo 20: erica l. mayer, md, mph
-
7:43
study of abemaciclib for patients with rb-positive, triple negative metastatic breast cancer
-
5:38
cdk4/6 inhibitors in metastatic breast cancer
-
1:43
composite biomarkers predictive of palbociclib endocrine treatment benefit in early breast cancer
-
1:00:06
metastatic breast cancer forum 2018: er breast cancer | dana-farber cancer institute
-
27:44
new targeted agents in breast cancer palbociclib & beyond
-
3:03
integrating palbociclib into the treatment of breast cancer
-
1:00
dr. tolaney on remaining questions with cdk4/6 inhibitors in hr /her2- breast cancer
-
45:07
metastatic breast cancer forum 2018: welcome and overview | dana-farber cancer institute
-
5:34
cdk4/6 inhibitors in metastatic breast cancer